Because of the progressive nature of type 2 diabetes, basal insulin alone may not be able to provide sufficient glycemic control over the long term, and thus insulin regimens will typically need to be intensified—especially for controlling postprandial glucose excursions. In patients with type 2 diabetes requiring more intensive intervention, insulin analog premix formulations can offer a simple, effective, and convenient option for tighter management of hyperglycemia in lieu of a traditional basal–bolus regimen.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care, 2011; 34,Suppl 1:S11–S61.
2.
Centers for Disease Control and Prevention: National Diabetes Fact Sheet, 2007. Atlanta: U.S. Department of Health and Human Services, 2007.
3.
Centers for Disease Control and Prevention: National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2011 December 6.
4.
BoyleJP, ThompsonTJ, GreggEW, BarkerLE, WilliamsonDF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr, 2010; 8:29.
5.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2011; 34,Suppl 1:S62–S69.
6.
BonoraE. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl, 2002; 12:5–11.
7.
DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999; 354:617–621.
8.
HanefeldM, FischerS, JuliusU, SchulzeJ, SchwanebeckU, SchmechelH, ZiegelaschHJ, LindnerJ. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia, 1996; 39:1577–1583.
9.
RodbardHW, JellingerPS, DavidsonJA, EinhornD, GarberAJ, GrunbergerG, HandelsmanY, HortonES, LebovitzH, LevyP, MoghissiES, SchwartzSS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract, 2009; 15:540–559.
10.
American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract, 2007; 13,Suppl 1:1–68.
11.
MonnierL, LapinskiH, ColetteC. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care, 2003; 26:881–885.
12.
NathanDM, BuseJB, DavidsonMB, FerranniniE, HolmanRR, SherwinR, ZinmanB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation, adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009; 32:193–203.
13.
MeneghiniL, KoenenC, WengW, SelamJL. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes—results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab, 2007; 9:902–913.
14.
Philis-TsimikasA, CharpentierG, ClausonP, Martinez RavnG, RobertsVL, ThorsteinssonB. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther, 2006; 28:1569–1581.
15.
PolonskyKS, GivenBD, van CauterE. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest, 1988; 81:442–448.
16.
DeWittDE, HirschIB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA, 2003; 289:2254–2264.
17.
GarberAJ. Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient. Diabetes Obes Metab, 2009; 11,Suppl 5:14–18.
18.
KazdaC, HulstrunkH, HelsbergK, LangerF, ForstT, HanefeldM. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications, 2006; 20:145–152.
19.
GarberAJ, WahlenJ, WahlT, BresslerP, BracerasR, AllenE, JainR. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)Diabetes Obes Metab, 2006; 8:58–66.
20.
Novo Nordisk Inc.: Novolin® 70/30 [prescribing information]. Princeton, NJ: Novo Nordisk Inc., 2010.
21.
Eli Lilly and Company: Humulin® 70/30 [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2007.
Eli Lilly and Company: Humalog® Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2009.
24.
Eli Lilly and Company: Humalog® Mix50/50 (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly and Company, 2009.
25.
HirschIB. Insulin analogues. N Engl J Med, 2005; 352:174–183.
26.
Vazquez-CarreraM, SilvestreJS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol, 2004; 26:445–461.
27.
GarberAJ, LigthelmR, ChristiansenJS, LieblA. Premixed insulin treatment for type 2 diabetes: analogue or human?Diabetes Obes Metab, 2007; 9:630–639.
28.
JacobsenLV, SogaardB, RiisA. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol, 2000; 56:399–403.
29.
HermansenK, ColomboM, StorgaardH, OstergaardA, KolendorfK, MadsbadS. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care, 2002; 25:883–888.
30.
HeiseT, HeinemannL, HovelmannU, BraunsB, NosekL, HaahrHL, OlsenKJ. Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy. Diabetes Care, 2009; 32:1431–1433.
31.
MaloneJK, YangH, WoodworthJR, HuangJ, CampaigneBN, HalleJP, YaleJF, GrossmanLD. Humalog® Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab, 2000; 26:481–487.
32.
CoscelliC, IacobellisG, CalderiniC, CarleoR, GobboM, DiMU, LeonettiF, GalluzzoA, PirroneV, LunettaM, CasaleP, PaleariF, FalcelliC, ValleD, CamporealeA, MeranteD. Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. Acta Diabetol, 2003; 40:187–192.
33.
MattooV, MilicevicZ, MaloneJK, SchwarzenhoferM, EkangakiA, LevittLK, LiongLH, RaisN, TounsiH. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract, 2003; 59:137–143.
34.
BoehmBO, HomePD, BehrendC, KampNM, LindholmA. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med, 2002; 19:393–399.
35.
MaloneJK, KerrLF, CampaigneBN, SachsonRA, HolcombeJH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther, 2004; 26:2034–2044.
36.
MaloneJK, BaiS, CampaigneBN, ReviriegoJ, Augendre-FerranteB. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med, 2005; 22:374–381.
37.
RoachP, MaloneJK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med, 2006; 23:743–749.
38.
ChristiansenJS, VazJA, MetelkoZ, BogoevM, DedovI. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab, 2003; 5:446–454.
39.
KannPH, WascherT, ZackovaV, MoellerJ, MeddingJ, SzocsA, MokanM, MrevljeF, RegulskiM. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes, 2006; 114:527–532.
40.
HolmanRR, ThorneKI, FarmerAJ, DaviesMJ, KeenanJF, PaulS, LevyJC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med, 2007; 357:1716–1730.
41.
RaskinP, AllenE, HollanderP, LewinA, GabbayRA, HuP, BodeB, GarberA. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005; 28:260–265.
42.
RosenstockJ, AhmannAJ, ColonG, Scism-BaconJ, JiangH, MartinS. Advancing insulin therapy in type 2 diabetes, previously treated with glargine plus oral agents: prandial premixed (lispro/ILPS) vs. basal/bolus (glargine/lispro) therapy. Diabetes Care, 2008; 31:20–25.
43.
MiserWF, ArakakiR, JiangH, Scism-BaconJ, AndersonPW, FahrbachJL. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther, 2010; 32:896–908.
44.
KhutsoaneD, SharmaSK, AlmustafaM, JangHC, AzarST, DanciulescuR, ShestakovaM, AyadNM, GulerS, BechOM. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab, 2008; 10:212–222.
45.
JangHC, GulerS, ShestakovaM. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract, 2008; 62:1013–1018.
46.
GumprechtJ, BenroubiM, BorziV, KawamoriR, ShabanJ, ShahS, ShestakovaM, WenyingY, LigthelmR, ValensiP. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract, 2009; 63:966–972.
